Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
Open Access
- 15 February 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (4) , 1297-1307
Abstract
Purpose: Despite recent progress, colon cancer is often resistant to combination chemotherapy, highlighting the need for development of novel therapeutic approaches. An attractive target is hypoxia-inducible factor-1α (HIF-1α), a key transcription factor with a pivotal role in tumor cell metabolism. One potential class of therapeutic agents targeting HIF-1α are mammalian target of rapamycin inhibitors such as rapamycin. A second class are topoisomerase I inhibitors, such as irinotecan, which are able to inhibit the accumulation of HIF-1α. We here investigated whether combination of rapamycin and irinotecan was active in human colon cancer models.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Ras mediates cell survival by regulating tuberinOncogene, 2007
- Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingBlood, 2006
- AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cellsOncogene, 2006
- Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent mannerCancer Cell, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor TemsirolimusCancer Research, 2006
- CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF SignalingNeoplasia, 2006
- Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cellsThe FASEB Journal, 2005
- Intensive Systemic Chemotherapy Combined With Surgery for Metastatic Colorectal Cancer: Results of a Phase II StudyJournal of Clinical Oncology, 2005
- On the Origin of Cancer CellsScience, 1956